Adverse reactions of terbutaline sulfate for injection

Terbutaline sulfate for injection is often used to treat and relieve bronchial asthma. It has a good therapeutic effect on emphysema and reversible bronchospasm. When using the medicine, you must be aware of some adverse reactions and precautions. A small number of patients may experience symptoms of dizziness, nausea, and drowsiness. It may cause palpitations, tachycardia and other adverse reactions to the cardiovascular system. Attention should be paid to this aspect.

Adverse Reactions

According to the recommended dosage, the incidence of adverse reactions is low, most of which are mild and tolerable and do not affect continued treatment. The main symptoms are: Central nervous system: tremor, nervousness, dizziness, headache, and occasional drowsiness. Cardiovascular system: palpitations, tachycardia. Respiratory system: Chest discomfort may occur, dyspnea is rare, hypersensitivity reactions and bronchospasm have been reported occasionally. Digestive system: nausea and vomiting. Systemic manifestations: fatigue, facial flushing, sweating, and pain at the injection site. Elevated liver aminotransferases and allergic vasculitis are occasionally seen.

Precautions

Like other sympathomimetic amines, terbutaline should be used with caution in patients with cardiovascular disease, including ischemic heart disease, hypertension, arrhythmias; patients with hyperthyroidism and diabetes; patients with abnormal responses to sympathomimetic amines; and patients with convulsions. Some patients may experience significant changes in systolic and diastolic blood pressure after administration of beta-adrenergic bronchodilators. There have been reports of patients experiencing allergic reactions and worsening bronchospasm immediately after taking terbutaline. Beta-adrenergic agonists have the potential to cause hypokalemia, possibly via intracellular shunting, which may lead to adverse cardiovascular effects. The decrease in serum potassium is usually temporary and does not require replacement. High doses of intravenous terbutaline may exacerbate pre-existing diabetes and ketoacidosis.

Pregnant and lactating women

In reproduction studies in mice and rabbits, there was no evidence of impairment of fertility or effects on the fetus following subcutaneous administration of doses up to 1500 times the maximum daily dose in adults. When terbutaline was given intravenously to laboring baboons at a dose four times the maximum subcutaneous dose for adults, increases in maternal and fetal blood glucose were observed, but there are no adequate controlled trials to confirm this in pregnant women. Since animal reproduction tests are not always consistent with human responses, pregnant women should only consider using it when it is really necessary and the pros and cons should be carefully weighed. It is not clear whether this product is excreted into human milk; use with caution in lactating women.